Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2020 | INSIGHT-MM: real-world patterns of patient characteristics

Noemí Puig • 23 Jun 2020
EHA 2020
Multiple Myeloma
INSIGHT-MM

Noemí Puig, MD, PhD, of the University Hospital Salamanca, Salamanca, Spain, discusses frailty in patient populations, and their under-representation in clinical trials as well as INSIGHT-MM (NCT02761187), a study evaluating the treatment and survival of multiple myeloma patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Noemí Puig

Methods for using mass spectrometry in the PB versus MRD in the bone marrow in multiple myeloma
2:17
Methods for using mass spectrometry in the PB versus MRD in the bone marrow in multiple myeloma
Noemí Puig • 18 Sep 2025
Evidence supporting the use of MRD-guided treatment in multiple myeloma: GEM2014MAIN and AURIGA
3:49
Evidence supporting the use of MRD-guided treatment in multiple myeloma: GEM2014MAIN and AURIGA
Noemí Puig • 18 Sep 2025
Investigating the use of mass spectrometry & NGF to measure MRD and predict outcomes in HR-SMM
2:20
Investigating the use of mass spectrometry & NGF to measure MRD and predict outcomes in HR-SMM
Noemí Puig • 7 Oct 2024
The value of mass spectrometry in multiple myeloma & how this may impact clinical practice
1:49
The value of mass spectrometry in multiple myeloma & how this may impact clinical practice
Noemí Puig • 7 Oct 2024

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Noemí Puig • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Noemí Puig • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Noemí Puig • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Noemí Puig • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals